{"analyses":[{"ciLowerLimit":"0.41","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.64","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment A over Treatment C","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.51","statisticalMethod":"Stratified Log-Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.45","upperLimit":"24.94","value":"16.59"},{"groupId":"OG001","lowerLimit":"6.97","upperLimit":"9.69","value":"8.31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"323"},{"groupId":"OG001","value":"328"}],"units":"Participants"}],"description":"PFS is defined as the time from date of randomization to the first documented tumor progression date or death due to any cause, whichever occurs first based on BICR assessment using RECIST v1.1. Participants who die without a reported progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment on or prior to initiation of subsequent anti-cancer therapy. Progressive disease (PD); 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD","id":"OG000","title":"Treatment A"},{"description":"Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle","id":"OG001","title":"Treatment C"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants of treatment A and treatment C","reportingStatus":"POSTED","timeFrame":"From randomization date to date of first documented tumor progression or death, whichever occurs first (Up to 31 months)","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}